Telehealth Reviews

Hers Weight Loss: What the Program Actually Costs, and What You Are Buying

By the US Health Digest editorial team · Published August 26, 2026 · Every claim linked to its primary source

Hers sells two separate subscriptions, and most price confusion comes from counting only one. Its terms state that the Weight Loss Membership and the Medication Plan “are charged as separate subscriptions,” that an active membership is required before a provider will evaluate you at all, and that the membership fee “does not include the cost of any prescription product” (Terms & Conditions, Internet Archive capture of July 13, 2026). On the storefront as captured on August 18, 2026 — forhers.com blocks automated retrieval, so no price here is a live reading — membership was $39 for the first month, then $149/month, and medication started at $149/month for an oral option and $299/month for tirzepatide (Internet Archive capture of forhers.com/weight-loss). In March 2026 the company said it “will no longer advertise compounded GLP-1 offerings on its platform or in its marketing,” keeping access for a limited set of customers if a provider determines a compounded product is clinically necessary (Form 8-K, Exhibit 99.1, March 9, 2026); its August 2026 quarterly report says compounded GLP-1s remain available “on a limited scale” and that it “currently only use[s] 503A compounding pharmacies” for them (Form 10-Q, August 2026). US Health Digest has no affiliate or commercial relationship with Hims & Hers Health, Inc.

Our Ro vs Noom Med vs Found head-to-head does not cover Hers; this page fills that gap. On method: forhers.com blocks automated retrieval, so every Hers figure on this page, including the summary above, was read on an Internet Archive capture of the company’s own page, capture date stated each time and no newer capture available on August 26, 2026. Competitor figures were fetched live on August 26, 2026. No figure here comes from a review site or aggregator.

Two subscriptions, not one

The terms are explicit, and the structure is the whole story. The Weight Loss Membership buys “clinical services and related Platform-facilitated support services... for a recurring monthly fee”; a separately billed Medication Plan buys the drug. And: “An active monthly Weight Loss Membership is required to be evaluated by a Provider for a prescription and to purchase and continue with a Medication Plan” (Terms & Conditions, capture of July 13, 2026). You pay the service fee before anyone tells you whether you qualify; the storefront states that membership “does not include or guarantee a prescription.”

Per the same terms, the fee covers an initial telehealth evaluation, monthly clinical check-ins, dosage-adjustment visits as needed, unlimited provider messaging, care team support and access to a private Hims & Hers Facebook weight-loss community; the storefront adds in-app weight tracking and a smart scale described as a $55 value. Cancellation runs one way: cancelling the Medication Plan does not cancel the Membership, which “will continue to renew monthly until you cancel,” while cancelling the Membership does cancel the Medication Plan. Either needs at least two days’ notice before the next billing date, there are no refunds for partial periods, and a medication refund exists only within 48 hours of an initial order or two days before a renewal.

The arithmetic, run twice

Using only figures published on the company’s storefront as captured on August 18, 2026, holding the advertised entry price constant:

Configuration A — oral semaglutide (Wegovy® Pill), advertised from $149/month. Month one is $39 membership + $149 medication = $188. Every month after is $149 + $149 = $298. Twelve months is $188 + (11 × $298) = $3,466.

Configuration B — tirzepatide (Zepbound® KwikPen®), advertised from $299/month. Month one is $39 + $299 = $338. Every month after is $149 + $299 = $448. Twelve months is $338 + (11 × $448) = $5,266.

The service layer alone — membership without medication, which the terms permit — is $39 + (11 × $149) = $1,678 a year: 48% of configuration A’s total.

What those totals exclude, on the company’s own account. Dose: the storefront prices are “from” prices; the Wegovy Pill page shows a dose ladder of 1.5, 4, 9 and 25 mg, and states in its FAQ that “Pricing may vary by dosage.” We found no published dose-by-dose price ladder on any Hers page we could verify, so the maintenance-dose cost is not knowable in advance from the site — a real gap, since Ro sells the same products and does publish dose-stepped prices (its Wegovy pen is $199/month at 0.25–0.5 mg and $349/month at 1–2.4 mg). Tax and shipping: the terms make you liable for “shipping and handling charges, if any, shown at the time you make a purchase,” and separately for “any applicable sales, use, duty, customs or other governmental taxes,” estimated at checkout and adjustable afterwards. No shipping figure was verifiable. Labs: the terms treat Lab “Testing Services” as separately purchased products with their own refund rules, not a membership benefit. Insurance — because there is none.

Two storefront listings sit far outside these ranges: Mounjaro® and Zepbound® at $1,899/month, against $299/month for the Zepbound KwikPen. The storefront prices these listings without comment and nothing we could read explains the gap, so we will not guess at it. What US cash prices for these drugs look like is mapped in our 2026 guide to GLP-1 costs without insurance.

Cash only, by design

Hers is not an insurance-navigation product, and the terms say so structurally: “Hims & Hers and the Medical Groups are not enrolled with, and are not participating providers with, any federal or state healthcare programs (i.e., Medicare, Medicaid) or commercial payers... By choosing to use the Service, you are specifically choosing to obtain products and services on a cash basis outside of any federal or state healthcare program or commercial payer.” The storefront puts it in marketing form — “Insurance isn’t required, so there are no complicated insurance questions or health insurance plan considerations” — and suggests paying by card and seeking FSA/HSA reimbursement yourself. If your plan covers Wegovy or Zepbound, the real comparison is $448/month against a copay. Found publishes a $49-a-month insurance-option plan, and Ro states that “only the Wegovy pen, Zepbound autoinjector pen, and Ozempic are available for insurance coverage through Ro,” with prior authorization “about 1–2 weeks” (both verified August 26, 2026). Check your benefit first: our coverage guide and denial-appeal walkthrough.

One routing detail the terms disclose and the marketing does not: where a product is available only through “certain manufacturer self-pay pharmacy solutions programs,” the prescription may go to Gifthealth®, Inc., an independent third-party pharmacy. Then “any medication-related purchase, billing, and fulfillment will be conducted directly between you and Gifthealth,” you handle cancellations and refunds with Gifthealth, and cancelling there does not cancel your Hers membership — so it is possible to stop paying for the drug and keep paying $149/month for the service.

Branded or compounded — what is actually being supplied

This distinction matters most clinically, and the answer changed in 2026. In a press release filed with the SEC on March 9, 2026, the company announced a Novo Nordisk collaboration and said it “will no longer advertise compounded GLP-1 offerings on its platform or in its marketing,” keeping them only “for what is anticipated to be a limited set of customers whose clinical needs cannot be met” by approved products (Exhibit 99.1 to Form 8-K). The August 2026 quarterly report adds that it “currently only use[s] 503A compounding pharmacies” for compounded GLP-1s, which it began offering in May 2024. Every product on the storefront capture we reviewed was branded and FDA-approved. So: branded by default, compounded by exception.

That exception carries the standing caveat. Compounded drugs are not FDA-approved; the agency “does not review compounded drugs for safety, effectiveness or quality before they are marketed,” and as of May 31, 2026 had received 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide (FDA). On April 30, 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list; the comment period closed July 30, 2026 and the docket shows no final action as of today — it remains a proposal (Federal Register 2026-12937). What turns on it is in compounded vs branded GLP-1s in 2026.

The company discloses the history behind that pivot itself. Its 10-Q says that in the FDA’s February 6, 2026 statement on restricting GLP-1 ingredients used in mass-marketed non-approved compounded drugs, “we were directly named” — the statement refers to “companies — including Hims & Hers and other compounding pharmacies” (FDA). The filing adds that the HHS General Counsel said HHS had referred the company to the DOJ for investigation, that “it is unclear what actions the FDA, HHS, or DOJ may take,” and that Novo Nordisk’s semaglutide patent suit was “voluntarily dismissed… without prejudice” on March 9, 2026. None of that establishes wrongdoing: a referral is not a charge, a dismissal is not a finding. It is why today’s product does not resemble the 2024 one.

How the clinical review actually works

Asynchronous by default. Asked whether video visits are required, the Wegovy Pill page answers: “Depending on your state, treatment may be determined without a video visit. If a visit is needed, scheduling a video or audio appointment is simple and convenient. If prescribed, a provider will be just a message away for follow-ups, adjustments, and ongoing support. Response times may vary.” The published flow is: join the membership; answer health questions that a provider reviews; get a plan if prescribed; get delivery. You pay first, fill in a questionnaire, and a state-licensed provider you have not met decides. The terms set the ongoing cadence at monthly check-ins plus dosage visits as needed, with unlimited messaging between.

Asynchronous care is legal, common and not automatically inferior — but it shifts the burden of surfacing contraindications onto an intake form. What a real review ought to check (personal and family history of medullary thyroid carcinoma or MEN2, pancreatitis, gallbladder disease, pregnancy or pregnancy plans, other GLP-1 use, a documented escalation plan) is set out in what happens in a GLP-1 medical review; judge any program on whether its intake asks. See also how GLP-1 telehealth works.

The marketing, beside the trial data

The storefront leads with a headline pounds figure and an asterisk. The footnote: “In a 71-week clinical study of Wegovy® oral semaglutide (25mg), adults with overweight or obesity lost on avg. 13.6% body weight alongside diet and exercise. Individual results may vary. Stopping treatment may result in weight regain.” That 13.6% is the primary, treatment-policy result of OASIS 4, which randomised 307 adults with co-primary endpoints at week 64, inside a 71-week trial (NEJM 2025; NCT05564117). It is the honest estimand — but the footnote omits the comparator (placebo lost 2.2%, a difference of 11.4 percentage points) and the tolerability picture (gastrointestinal adverse events in 74.0% of the semaglutide group versus 42.2% on placebo).

For the injectables the reference points are STEP 1 — semaglutide 2.4 mg averaging 14.9% body-weight reduction at 68 weeks versus 2.4% with placebo, treatment-policy estimand (NEJM 2021); women were 1,453 of its 1,961 participants, a figure that sits in the registry rather than the paper (NCT03548935) — and SURMOUNT-1, tirzepatide 15 mg averaging 20.9% at 72 weeks versus 3.1% with placebo, treatment-regimen estimand (NEJM 2022). Separate trials, different estimands and populations, not a head-to-head, none run through a telehealth membership. Drug and dose, not program, are the larger clinical variables. In SURMOUNT-4, participants withdrawn from tirzepatide regained a substantial share of what they had lost (JAMA 2024).

Two further items are marketing, not evidence. The dose-ladder module says early nausea “means the medication is working”; no trial we cite establishes side effects as an indicator of effect. And the page carries member testimonials with short-run pound-loss figures under the disclosure “Customers may have been compensated. Results have not been independently verified.” That disclosure is the useful part — see the FTC’s gut-check guide and our piece on spotting fake weight-loss testimonials.

Beside the programs we have already covered (as of August 26, 2026)

Cancellation terms for Ro, Noom and Found were not re-verified today and are therefore not in the table; they are in our head-to-head, verified August 14, 2026. One figure there has already moved: Noom’s branded tier was $99/month on August 14 and is $129/month on August 26. A 30% change in twelve days is why we date every figure and re-verify rather than reuse.

Who this is and is not rational for

The structure suits a specific person: no GLP-1 coverage, wants a branded FDA-approved product at self-pay pricing without assembling the pieces herself, values messaging and a monthly check-in over scheduled video time, and can absorb roughly $300–$450 a month indefinitely. For her the $149 fee buys a real thing — prescribing, titration, side-effect management, a route to a pharmacy — and the arithmetic above is its honest price.

It works against others. If insurance covers GLP-1s for you, a program that does not bill insurance forfeits your largest saving, and a prior-authorisation-capable competitor is the more rational comparison. If your budget cannot absorb a dose-driven price rise you cannot see in advance, the missing dose ladder is a risk, not a technicality. If you want scheduled clinician video time, a model that says treatment “may be determined without a video visit” is not built for you. If you are considering a compounded product, you would be entering the narrow exception the company itself describes, under an FDA proposal still pending. And if you are planning a pregnancy in the next year, GLP-1s are not used in pregnancy — that belongs at intake, not after the first shipment (why).

We are not telling you to sign up or not to. The comparison that decides it is your own insurance benefit against these cash numbers. Broader options: our 2026 comparison of GLP-1 telehealth programs for women and GLP-1 FAQ for women.

Questions to ask before you pay the first $39

• What will the medication cost at my maintenance dose, not my starting dose — in writing, before I pay?
• If a provider finds me ineligible after I have paid the membership fee, what is refunded?
• Will my prescription be filled by the platform’s pharmacy or a third-party one, and who bills me?
• Is the product FDA-approved branded medication or compounded? If compounded, which pharmacy and under which pathway?
• Does my own plan cover Wegovy or Zepbound, and what is the copay after prior authorization?
• What is the escalation schedule, and what happens to billing if I hold at a lower dose for side effects?
• If I cancel the medication plan, is the $149 membership still billing? (Per the terms: yes, until you cancel it separately.)
• Am I planning pregnancy in the next year, and did the intake ask me?

Sources